Pfizer [PFIZER] vs Gland Pharma [GLAND] Detailed Stock Comparison

Pfizer Ltd.

NSE
Loading...

Gland Pharma Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Pfizer Ltd. wins in 11 metrics, Gland Pharma Ltd. wins in 9 metrics, with 0 ties. Pfizer Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Pfizer Ltd. Gland Pharma Ltd. Better
P/E Ratio (TTM) 25.56 34.86 Pfizer Ltd.
Price-to-Book Ratio 5.66 3.09 Gland Pharma Ltd.
Debt-to-Equity Ratio 2.33 3.16 Pfizer Ltd.
PEG Ratio 2.28 0.58 Gland Pharma Ltd.
EV/EBITDA 22.48 18.80 Gland Pharma Ltd.
Profit Margin (TTM) 34.39% 13.86% Pfizer Ltd.
Operating Margin (TTM) 33.17% 19.30% Pfizer Ltd.
EBITDA Margin (TTM) 33.17% 19.30% Pfizer Ltd.
Return on Equity 18.20% 7.63% Pfizer Ltd.
Return on Assets (TTM) 15.63% 6.22% Pfizer Ltd.
Free Cash Flow (TTM) $6.32B $5.21B Pfizer Ltd.
Dividend Yield 1.27% 1.95% Gland Pharma Ltd.
1-Year Return -23.35% 33.88% Gland Pharma Ltd.
Price-to-Sales Ratio (TTM) 8.78 4.84 Gland Pharma Ltd.
Enterprise Value $194.17B $266.81B Gland Pharma Ltd.
EV/Revenue Ratio 7.82 4.37 Gland Pharma Ltd.
Gross Profit Margin (TTM) 65.15% 65.99% Gland Pharma Ltd.
Revenue per Share (TTM) $543 $371 Pfizer Ltd.
Earnings per Share (Diluted) $186.40 $51.50 Pfizer Ltd.
Beta (Stock Volatility) 0.17 0.41 Pfizer Ltd.

Pfizer Ltd. vs Gland Pharma Ltd. Stock Performance Analysis

Loading Price Chart...

PFIZER
GLAND

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Pfizer Ltd.0.20%-0.22%-8.81%-4.87%-9.94%-8.09%
Gland Pharma Ltd.-2.31%-1.82%18.29%37.34%32.35%28.86%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Pfizer Ltd.-23.35%16.94%-16.55%139.64%232.33%479.18%
Gland Pharma Ltd.33.88%124.19%-26.40%24.33%24.33%24.33%

Performance & Financial Health Analysis: Pfizer Ltd. vs Gland Pharma Ltd.

MetricPFIZERGLAND
Market Information
Market Cap i₹218.82B₹295.80B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i14,47098,026
90 Day Avg. Volume i18,45091,782
Last Close₹4,518.00₹2,210.00
52 Week Range₹4,396.70 - ₹5,993.00₹1,573.60 - ₹2,396.00
% from 52W High-24.61%-7.76%
All-Time High₹6,451.15 (Sep 02, 2024)₹4,350.00 (Aug 09, 2021)
% from All-Time High-29.97%-49.20%
Growth Metrics
Quarterly Revenue Growth0.20%0.23%
Quarterly Earnings Growth0.11%0.28%
Financial Health
Profit Margin (TTM) i0.34%0.14%
Operating Margin (TTM) i0.33%0.19%
Return on Equity (TTM) i0.18%0.08%
Debt to Equity (MRQ) i2.333.16
Cash & Liquidity
Book Value per Share (MRQ)₹841.24₹580.47
Cash per Share (MRQ)₹591.12₹194.34
Operating Cash Flow (TTM) i₹9.08B₹7.50B
Levered Free Cash Flow (TTM) i₹7.68B₹6.99B
Dividends
Last 12-Month Dividend Yield i1.27%1.95%
Last 12-Month Dividend i₹70.00₹38.00

Valuation & Enterprise Metrics Analysis: Pfizer Ltd. vs Gland Pharma Ltd.

MetricPFIZER (Apr 24, 2026)GLAND (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i25.5634.86
Forward P/E i25.1525.03
PEG Ratio i2.280.58
Price to Sales (TTM) i8.784.84
Price to Book (MRQ) i5.663.09
Market Capitalization
Market Capitalization i₹218.82B₹295.80B
Enterprise Value i₹194.17B₹266.81B
Enterprise Value Metrics
Enterprise to Revenue i7.824.37
Enterprise to EBITDA i22.4818.80
Risk & Other Metrics
Beta i0.170.41
Book Value per Share (MRQ) i₹841.24₹580.47

Financial Statements Comparison: Pfizer Ltd. vs Gland Pharma Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPFIZER (2025)GLAND (2025)
Revenue/Sales i22.81B55.84B
Cost of Goods Sold i8.13B20.90B
COGS % of Revenue i35.6%37.4%
Gross Profit i14.68B34.93B
Gross Margin i64.4%62.6%
Research & Development iN/A332.84M
Operating Income (EBIT) i6.81B8.90B
Operating Margin i29.9%15.9%
EBITDA i9.13B14.76B
EBITDA Margin i40.0%26.4%
Pre-Tax Income i10.16B10.63B
Pre-Tax Income % of Revenue i44.5%19.0%
Income Tax i2.48B3.64B
Income Tax % of Revenue i10.9%6.5%
Net Income (Profit) i7.68B6.99B
Profit Margin i33.7%12.5%

Balance Sheet & Liquidity Metrics

MetricPFIZER (2025)GLAND (2025)
Cash & Equivalents i4.95B25.56B
Total Current Assets i35.13B67.83B
Total Current Assets % of Revenue i154.0%121.5%
Total Current Liabilities i5.70B15.65B
Total Current Liabilities % of Revenue i25.0%28.0%
Long-Term Debt i676.20M1.07B
Long-Term Debt % of Revenue i3.0%1.9%
Total Shareholders Equity i42.17B91.51B
Retained Earnings i24.36B71.57B
Retained Earnings % of Revenue i106.8%128.2%
Property, Plant & Equipment i1.72B3.59B

Cash Flow Statement Comparison

MetricPFIZER (2025)GLAND (2025)
Operating Cash Flow i9.08B7.50B
Operating Cash Flow % of Revenue i39.8%13.4%
Capital Expenditures i1.24B-3.84B
Free Cash Flow i6.32B5.21B
FCF Margin i27.7%9.3%
Debt Repayment iN/A-628.24M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricPFIZERGLAND
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i45.75M164.76M
Float Shares i15.10M79.36M
% Held by Insiders i66.98%51.84%
% Held by Institutions i16.80%36.58%
% Held by Public i16.22%11.58%

Dividend Analysis & Yield Comparison: Pfizer Ltd. vs Gland Pharma Ltd.

MetricPFIZERGLAND
Last 12-Month Dividend i₹70.00₹38.00
Last 12-Month Dividend Yield i1.27%1.95%
3-Year Avg Annual Dividend i₹46.67₹12.67
3-Year Avg Dividend Yield i0.58%1.00%
3-Year Total Dividends i₹140.00₹38.00
Ex-Dividend DateJul 09, 2025Aug 14, 2025